cancun hoc 2016 - incan-mexico.org hoc 2016.pdframiro espinoza, md 13:00-13:40 magistral conference...

Faculty

Faculty INCan

Dr. Abelardo Meneses GarcíaDirector General

Dr. Eduardo E. Cervera CeballosDirector de Docencia

Dra. Silvia Rivas VeraJefa del Departamento de Hematología

Dr. Jorge O. García MéndezJefe del Departamento de Educación

Médica Continua

Dra. Myrna Candelaria HernándezCoordinadora de la Unidad Funcional

de Hematología

Dr. Sergio Sánchez GuerreroJefe del Departamento de Banco de

Sangre

Dr. Juan R. Labardini MéndezDepartamento de Hematología

Dr. Luis Manuel Valero SaldañaCoordinador del Programa de

Trasplante de Progenitores Hematopoyéticos

Dra. Nidia P. Zapata CantoDepartamento de Hematología

Dra. Ana Florencia Ramírez IbargüenDepartamento de Hematología

Dra. Patricia Baz GutiérrezDepartamento de Hematología

Dr. Ramiro Espinoza ZamoraDepartamento de Hematología

Dra. Karla Espinosa BautistaDepartamento de Hematología

Dr. Carlos Cadena EumañaDepartamento de Hematología

Dr. Flavio Grimaldo GómezDepartamento de Hematología

Faculty National

Dra. Magdalena Bahena GarcíaHospital de Central Sur de Alta

Especialidad de Petróleos MexicanosCiudad de México

Dra. Florencia DelgadoDirector de Asuntos Científicos

“Latinoamérica”

Dra. María Roberta Demichelis Gómez

Instituto Nacional de Ciencias Médicas y Nutrición

“Salvador Zubirán”, Ciudad de México

Dr. Freddy Domínguez Sosa Hospital de Central Sur de Alta


Dr. Arturo Galindo Fraga Instituto Nacional de Ciencias Médicas

y Nutrición“Salvador Zubirán”, Ciudad de México

Dr. Renán Góngora BiachiGHEMAS, Mérid, Yuc.

Dr. Pedro González TorresGHEMAS. Mérida, Yuc.

Dr. Luis M. Loarca PiñaHospital Ángeles de Querétaro, Qro.

Dra. Norma López-SantiagoInstituto Nacional de Pediatría, Ciudad

de México

Dr. Gerardo LópezInstituto Nacional de Pediatría, Ciudad

de México

Faculty

Dr. Francisco J. Mijangos HuescaHospital de Central Norte de Alta


Dr. Roberto Ovilla MartínezHospital Ángeles de Interlomas,

Ciudad de México

Dr. Oscar de J. Pérez Ramírez CReHCe, San Luis Potosí

Dr. Ramón Rivas LlamasPresidente de la Agrupación Mexicana

para el Estudios de la HematologíaHospital General, Culiacán, Sin.

Dra. Margarita Rodríguez MejoradaGHEMAS, Mérida Yuc.

Dr. Jorge Vela OjedaHospital de Especialidades CMN La

Raza, IMSS

Dr. Luis Mario Villela MartínezHospital General “Fernando

Ocaranza”, ISSSTE, Hermosillo, Son.

Dra. Yenet VenturaInstituto Nacional de Ciencias Médicas

y Nutrición“Salvador Zubirán”, Ciudad de México

Faculty International

Jorge Cortés, MDMD Anderson Cancer Center,

Houston Tx

Luis Fayad, MDMD Anderson Cancer Center,

Houston TxRafael Fonseca MD

Mayo Clinic, Scottsdale AZ, Phoenix

Guillermo García-Manero, MDChief Section of MDS

Deputy Chair Translational ResearchMD Anderson Cancer Center,

Houston Tx

Irene M. Ghobrial, MDAssociate Professor, Medicine, Harvard

Medical SchoolActive Medical Staff, Myeloma Program, Dana-Farber Institute

Hagop Kantarjian, MDProfessor and Chairman Department of

LeukemiaSamsung Distinguished University

Chair in Cancer MedicineMD Anderson Cancer Center,

University of Texas

Partow Kebriaei MDMD Anderson Cancer Center,

Houston Tx

Cesar Nuñez, MDMD Anderson Cancer Center,

Houston Tx

Farhad Ravandi-Kashani, MDChief, Section of Developmental

Therapeutics,Department of Leukemia,

University of Texas – M. D. Anderson Cancer Center

Hilario Mata, MD, PhDMD Anderson Cancer Center,

Houston Tx

Rubén Niesvizky MDDirector Multiple Myeloma Center

Professor of MedicineWeill Cornell Medical College

New York Presbyterian Hospital

Professor

Mapping

Program

August 31/ Wednesday

Mexican PNH Working Group MeetingRoom: Coral Garden

17:00 – 20:00 (By an unrestricted scientific grant by Alexion)

September 1st/Thursday

Mexican PNH Working Group MeetingRoom: Coral Garden

08:00 – 10:00(By an unrestricted scientific grant by Alexion)

By invitation only

Iberoamerican Multiple Myeloma Consortium Annual MeetingRoom: Coral Garden

Coordinators: Eduardo Cervera, MD / Nidia Zapata, MD10:30 – 13:30

OPENING CEREMONYAbelardo Meneses, MD/ Hilario Mata, MD18:00 – 20:00

18:00- 18:15 Welcome Address Instituto Nacional de Cancerología Abelardo Meneses, MD PhD

18:15 – 18: 55 The paradigm of drug pricing in oncology Hagop Kantarjian, MD

18:55- 19:05 Welcome Address Md Anderson Cancer Center Hilario Mata, MD PhD

19:05 – 19:55 Music in Medicine Claudius Conrad, MD PhD

Welcome & Exposition Inaugural Cocktail20:00 – 21:00

September 2nd/Friday

BREAKFAST SYMPOSIUMRoom: Coral Garden

(Satellite symposium by an unrestricted educational grant from Roche Pharmaceuticals)

07:30 - 08:20

RELAPSE/REFRACTORY FOLLICULAR LYMPHOMA: Optimizing Patients Outcomes With Novel anti CD20 antibodies.Coordinator: Oscar Pérez Ramírez, MD.

07:30- 07:45 Breakfast

07:45- 08:20 Magistral conference Luis Fayad, MD

LYMPHOMARoom: Coral Garden

Coordinators: Magdalena Bahena, MD/ Silvia Rivas, MD08:30 – 09:50

08:30 – 08:40 Interactive Clinical case discussion Ana Florencia Ramírez, MD

08:40 – 09:00 Treatment of aggressive NHL, including double hit lymphoma Luis Fayad, MD

09:00 – 09:20 Mantle cell lymphoma. Impact of small molecules on survival Luis Villela, MD

09:20 – 09:40 R-CHOP: does one size fit all in diffuse large B cell Lymphoma? Adrián Ceballos, MD

09:40 – 09:50 Questions & Answers (Round Table) All of the Participants


INFECTIOUS DISEASESRoom: Coral Garden

Coordinators: Jorge García, MD/ Luis Loarca, MD09:50 – 11:10

09:50 – 10:10 Reactivation of latent infectious diseases with immunochemotherapy: TB, HBV, etc. Freddy Domínguez, MD

10:10 – 10:30 Treatment and contraindication of chemotherapy in systemic fungal infections. Jorge García, MD

10:30 – 10:50 Impact on treatment of hematological malignancies of emergent epidemic diseases. Arturo Galindo, MD


11:10 – 11:20 Coffee Break

PEDIATRIC & YOUNG ADULTSRoom: Coral Garden

Coordinators: Karla Espinosa, MD/ Norma López, MD11:20 – 12:50

11:20 – 11:40 Interactive Clinical case discussion Gerardo López, MD

11:40 – 12:00 Incorporation of small molecules in the treatment of pediatric ALL. Cesar Nuñez, MD

12:00 – 12:20 Monoclonal antibodies in ALL. Roberta de Michelis, MD

12:20 – 12:40 Teenager & young adult lymphoma choosing treatment: like a big boy or an small adult? Ramiro Espinoza, MD.



MYELOMARoom: Coral Garden

Satellite lunch symposium(By an unrestricted educational grant from CELGENE)

12:50-13:00 Interactive Clinical Case Discussion Ramiro Espinoza, MD

13:00-13:40 Magistral Conference Irene M. Ghobrial, MD

13:40-14:00 Interactive Clinical Case Discussion Ramiro Espinoza, MD

MYELOMARoom: Coral Garden

Coordinators: Margarita Rodríguez, MD/ Jorge Vela, MD14:00 – 15:50

14:00 – 14:20 A critical reappraisal of new standard diagnostic criteria Florencia Delgado, MD

14:20 – 14:40 Interactive Clinical case discussion Margarita Rodríguez, MD

14:40 – 15:00 Investigative tools for diagnosis and management of MM Irene M. Ghobrial, MD

15:00 – 15:20 Insights into the Pathophysiology and Therapeutic Targeting of Treatment Resistance in Myeloma Rafael Fonseca, MD 15:20 – 15:40 A new Direction in treating Multiple Myeloma in the Era of novel Agents “A clinical Perspective” Rubén Niesvizky, MD



Room: Coral GardenAnnual Nominative Conference“Juan Labardini Méndez MD”

16:00 – 17:00 (A brunch cocktail will be served at the end)16:00 – 16:15 Who is Juan Labardini Méndez, “El Maestro”

Ramiro Espinoza, MD / Eduardo Cervera, MD

Presenter: Pedro González Martínez, MD (10')

16:25 – 17:00 HPN: New concepts of an old hematological disease Renán Góngora, MD

September 3rd/Saturday

TRANSPLANTATIONRoom: Coral Garden

Coordinators: Luis Manuel Valero, MD/ Roberto Ovilla, MD07:30 – 08:50

07:30 – 07:50 Minimal residual disease pre-& postrasplantation. Partow Kebriaei, MD

07:50 – 08:10 Haploidentical transplant in hematological malignancies Luis M. Valero, MD

08:10 – 08:30 Transplantation in Chilhood ALL: Experience at INP Gerardo López, MD

08:30 - 08:40 Interactive Clinical Case Discussion Karla Espinosa, MD


PLENARY SESSIONRoom: Coral Garden

08:50 – 10:30 Integrating new therapeutics tools: from chemo to immunological options Hagop Kantarjian, MD

ACUTE LEUKEMIARoom: Coral Garden

Coordinators: Luis M. Loarca, MD/ Ramón Rivas, MD10:30 – 11:30

10:30 – 10:40 Interactive Clinical case discussion Nidia Zapata, MD

10:40 – 11:00 Refractory AML. Treatment with FLT3 inhibitors Jorge Cortes, MD

11:00 – 11:20 Refractory AML. Treatment with no FLT3 inhibitors Farhad Ravandi, MD



11:30 – 11:40 Coffee Break

MDSRoom: Coral Garden

Coordinators: Francisco Mijangos, MD/ Patricia Baz, MD11:40 – 13:00

11:40 – 11:50 Interactive Clinical case discussion Fransisco Zazueta, MD

11:50 – 12:10 Quantifying the risk: Who patients requires less/more intensive treatment? Myrna Candelaria, MD

12:10 – 12:25 Mutations & cytogenetic alterations implicated in evolution to acute leukemia Farhad Ravandi, MD

12:25 – 12:40 Advances in treatment in MDS Guillermo García-Manero, MD

AMSDAC PRESENTATION (10')


September 3rd/SaturdayBest of ASCO

Hemato/Oncology AbstractsRoom: Coral Garden

13:00 – 15:00

13:00 – 13:15 Hematologic Malignancies Speaker: Flavio A. Grimaldo, MD

Abstract ID: 7000Jeffrey E. Lancet, MD., Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML.Abstract ID: 7001Andreas Hochhaus, MD., Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CMLCP) treated with frontline nilotinib: Results from the ENESTFreedom study.

13:15 – 13:30 Hematologic Malignancies Leukemia, Myelodysplastic Syndromes and, Allotransplant Speaker: Roberta de Michelis, MD

Abstract ID: 7008Jorge E. Cortes, MD., Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.Abstract ID: 7009Daniel Aaron Pollyea, MD., Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy.

Coordinator: Carlos Cadena, MD

13:30 – 13:45 Hematologic Malignancies Lymphoma and Chronic Lymphocytic Lymphoma Speaker: Ana Ramírez Ibarguen, MD

Abstract ID: 7501Adrienne Alise Phillips, MD., A prospective, multicenter, randomized study of anti-CCR4 monoclonal antibody mogamulizumab (moga) vs investigator's choice (IC) in the treatment of patients (pts) with relapsed/refractory (R/R) adult T-cell leukemia-lymphoma (ATL).


Abstract ID: 7503Mathias J. Rummel, MD., Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).

13:45 – 14:10 Hematologic Malignancies Lymphoma and Chronic Lymphocytic Lymphoma Speaker: Luis Villela, MD

Abstract ID: 7504Pieternella J. Lugtenburg, MD., Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B- cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.

Abstract ID: 7506Thomas E. Witzig, MD., PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

Abstract ID: 7508Steven i. Park, MD., A phase 2 trial of ABVD followed by brentuximab vedotin consolidation in limited stage non-bulky Hodgkin lymphoma.

Coordinator: Silvia Rivas Vera, MD

14:10 – 14:30 Hematologic Malignancies Plasma Cell Dyscrasia Speaker: Rafael Fonseca, M.D.

Abstract ID: LBA4Antonio Palumbo, MD., Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study.

Abstract ID: 8000Michael Cavo, MD., Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).


Abstract ID: 8001Michael Attal, MD., Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).

14:30 – 14:45 Hematologic Malignancies Plasma Cell Dyscrasia Speaker: Yanet Ventura, M.D.

Abstract ID: 8003Sham Mailankody, MD., Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients.

Abstract ID: 8009Ravi Vij, MD., A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.

Coordinator: Sergio Sánchez, M.D.

14:45 – 15:00 Pannel Discussion Q/A

DEBATE: EDUARDO CERVERA CEBALLOS, M.D.All of International guest Professors

September 4th/Sunday

MULTIPLE MYELOMA ADVISORY BOARD(By an unrestricted scientific grant by CELGENE)

By invitation only

Information & Online Register

www.incan-mexico.org

+52 (55) 5663-2803 / +52 (55) 5663-0402www.intermeeting.com.mx

CostSpecialists

$350.00 USDResidents

$150.00 USDTransfer or bank deposit

Banco SantanderInstituto Nacional de Cancerología

Cta. N° 65502136852CLABE: 014180655021368529

cancun hoc 2016 - incan-mexico.org hoc 2016.pdframiro espinoza, md 13:00-13:40 magistral conference...

Documents